The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIq-ai Ltd Regulatory News (IQAI)

Share Price Information for Iq-ai Ltd (IQAI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.65
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.10 (6.25%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1.65
IQAI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Imaging Biometrics and QMENTA announce partnership

13 Jun 2018 07:00

RNS Number : 1663R
Flying Brands Limited
13 June 2018
 

Flying Brands PLC

("Flying Brands" or the "Company")

Imaging Biometrics and QMENTA announce a partnership to increase accuracy in research.

 

Imaging Biometrics®, LLC ("IB"), a subsidiary of Flying Brands Limited (LON:FBDU), announces today that it has entered into a partnership to accelerate neuroscience research and increase accuracy in diagnostics support. Imaging Biometrics will integrate all IB modules; IB Neuro, IB Delta T1 Maps, IB Diffusion, and IB DCE onto the cloud-based QMENTA platform that provides advanced data analysis and management for neuro experts.

 

The integration of IB's software is the first FDA cleared option on the QMENTA platform to be uploaded via its Software Development Kit ("SDK"). The SDK has been developed by QMENTA's engineers to enable third party companies or researchers with algorithms to integrate them on the platform to easily share them with the neuroscience community. This goes along with QMENTA's aim to bolster collaboration, whether it be between researchers, neurologists, developers, or even with other companies.

 

Quote from Imaging Biometrics' CEO, Michael Schmainda

"Our partnership with QMENTA enables efficient and immediate access to our quantitative imaging solutions to those involved in clinical trials and research. It is exciting to be part of QMENTA's neuro-centric platform and helping advance the understanding of neurological disorders."

 

Quote from QMENTA's CEO, Paulo Rodrigues, PhD

"We are very proud of this new partnership as it is the first FDA cleared tool we will be implementing on our SDK. We believe this partnership will improve our customers' satisfaction, because they know they can trust and rely on powerful and efficient tools such as the ones that Imaging Biometrics is developing." 

About the partners

Imaging Biometrics, a subsidiary of Flying Brands Limited (LON:FBDU), develops and provides visualisation and analytical solutions that enable clinicians to better diagnose and treat diseases with greater confidence. Through close collaboration with top researchers and clinicians, sophisticated advancements are translated into platform-independent software plug-ins which can extend the base functionality of workstations, imaging systems, PACS, or medical viewers. By design, IB's advanced visualisation software seamlessly integrates into routine workflows. For more information about Imaging Biometrics, visit the company's website at www.imagingbiometrics.com.

 

QMENTA offers a cloud-based platform to streamline the medical imaging workflow for running clinical trials. QMENTA's aim is to accelerate the discovery and development of new treatments for neurological diseases using state-of-the-art image processing techniques. QMENTA has been growing since 2013 in EU & US, now supporting many multi-center studies and a number of clinical trials. The company was named "Best New Radiology Vendor" in 2017 by Aunt Minnie and was a European Winner for Accenture's Healthtech Innovation Challenge. More recently, QMENTA has been invited by Sanofi to attend VivaTech in Paris and won one of the Sanofi Tech Lab challenges for its innovative technology. For more information on the company, visit www.qmenta.com.

 

Flying Brands Limited (Ticker:FBDU) is the parent company of StoneChecker® and Imaging Biometrics® focused on advanced and state of the art medical software and services. (www.flyingbrands.co.uk).

 

The Directors of the Company accept responsibility for the contents of this announcement.

 

For further information, please contact:

Flying Brands Limited

Qu Li/Trevor Brown/Vinod Kaushal

Tel: 020 7469 0930

 

 

Peterhouse Corporate Finance (Financial Adviser and Broker)

Lucy Williams/Heena Karani

Tel: 020 7220 9797

 

 

 

-Ends-

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
STRGMGMVKZLGRZM
Date   Source Headline
10th May 20248:15 amRNSRare Pediatric Disease Designation Granted to GaM
2nd May 202412:47 pmRNSIB Announces Expanded Access Program for GaM
29th Apr 20243:26 pmRNSPublication of Annual Report
5th Mar 20247:00 amRNSGrant of Options
1st Mar 20248:22 amRNSHolding(s) in Company
1st Mar 20248:20 amRNSHolding(s) in Company
26th Feb 20247:00 amRNSResult of Broker Option and Total Voting Rights
22nd Feb 20247:00 amRNSPlacing and Broker Option
9th Feb 202412:49 pmRNSFDA Application Update
2nd Feb 20248:39 amRNSIB awarded a $100,000 grant
22nd Jan 202410:05 amRNSHolding(s) in Company
15th Jan 20247:01 amRNSDirector Dealings and Conversion of CLNs
15th Jan 20247:00 amRNSHolding(s) in Company
10th Jan 20247:00 amRNSIB Launching an Expanded Access Program for GaM
19th Dec 20232:29 pmRNSImaging Biometrics granted FDA “Fast-Track”
5th Dec 202310:58 amRNSIQ-AI Announces Positive Interim Phase 1 Results
20th Nov 20231:42 pmRNSHolding(s) in Company
9th Nov 202311:38 amRNSDirector Dealing and Conversion of CLNs
8th Nov 202310:59 amRNSApplication for Pediatric Rare Disease Designation
6th Nov 20231:02 pmRNSHolding(s) in Company
18th Oct 20232:29 pmRNSUpdate Regarding Imaging Biometrics LLC
13th Oct 20238:55 amRNSIB Letter to Shareholders
9th Oct 20237:00 amRNSOrphan Drug Status to GaM and Total Voting Rights
3rd Oct 202311:30 amRNSHolding(s) in Company
19th Sep 20232:32 pmRNSIQ-AI shares cease trading on the OTCQB
8th Sep 20237:00 amRNSReduced Gadolinium Approach Validated'
18th Aug 202312:06 pmRNSUpdate on Collaboration Agreement with Mayo Clinic
18th Aug 202311:20 amRNSIB & GE HealthCare Enter into Commercial Agreement
17th Aug 20237:00 amRNSHalf-year Report
19th Jul 20237:00 amRNSImaging Biometrics Installs IB Nimble™ For MCW
13th Jul 20237:00 amRNSOrphan Drug Designation for GaM in Pediatric GBM
27th Jun 20237:00 amRNSStudies Show GaM Inhibits Pediatric Tumor Growth
23rd May 202311:02 amRNSResult of AGM
23rd May 20237:00 amRNSAGM Statement
3rd May 20234:14 pmRNSNotice of AGM
26th Apr 20237:00 amRNSFinal Results
28th Feb 20233:52 pmRNSOrphan Drug Designation Status
13th Jan 20232:05 pmRNSSecond Price Monitoring Extn
13th Jan 20232:00 pmRNSPrice Monitoring Extension
13th Jan 202311:05 amRNSSecond Price Monitoring Extn
13th Jan 202311:00 amRNSPrice Monitoring Extension
10th Jan 20237:00 amRNSLetter to Shareholders
2nd Dec 202211:11 amRNSHolding in Company
25th Oct 202211:00 amRNSPrice Monitoring Extension
30th Sep 20227:00 amRNSLetter to Shareholders
26th Sep 20227:00 amRNSIssue of Warrants to Employees
16th Aug 20224:40 pmRNSSecond Price Monitoring Extn
16th Aug 20224:35 pmRNSPrice Monitoring Extension
16th Aug 20229:28 amRNSHalf-year Report
3rd Aug 20221:01 pmRNSTR1 - Notification of Major Holdings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.